ASPA
MCID: PTT049
MIFTS: 53

Pituitary Adenoma, Acth-Secreting (ASPA) malady

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Pituitary Adenoma, Acth-Secreting

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Pituitary Adenoma, Acth-Secreting:

Name: Pituitary Adenoma, Acth-Secreting 52 12
Acth-Secreting Pituitary Adenoma 11 48 70 39 13 68
Cushing Disease 48 25 54 70
Pituitary-Dependent Cushing Syndrome 48 54
Pituitary Corticotroph Micro-Adenoma 48 54
Corticotroph Pituitary Adenoma 48 54
Pituitary-Dependant Hypercortisolism Disorder 25
Pituitary-Dependent Cushing's Disease 68
Pituitary-Dependent Cushings Disease 50
Pituitary-Dependant Cushing Syndrome 25
Pituitary Dependent Cushing Syndrome 48
Pituitary-Dependant Hypercortisolism 25
 
Pituitary Acth-Secreting Adenoma 12
Acth-Producing Pituitary Adenoma 11
Pituitary Acth Hypersecretion 25
Adrenal Gland Hyperfunction 68
Pituitary Cushing Syndrome 25
Pituitary Cushing Disease 70
Corticotroph Adenoma 11
Cushing's Disease 48
Corticotropinoma 11
Hypercortisolism 25
Cushing Syndrome 68
Aspa 70

Characteristics:

Orphanet epidemiological data:

54
cushing disease:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult

Classifications:



External Ids:

OMIM52 219090
Disease Ontology11 DOID:7004
MeSH39 D049913
NCIt45 C7462
Orphanet54 ORPHA96253
SNOMED-CT62 21109002, 254958004
ICD10 via Orphanet31 E24.0, D35.2
MESH via Orphanet40 D047748
UMLS via Orphanet69 C0221406
MedGen37 C0221406

Summaries for Pituitary Adenoma, Acth-Secreting

About this section
Genetics Home Reference:25 Cushing disease is caused by elevated levels of a hormone called cortisol, which leads to a wide variety of signs and symptoms. This condition usually occurs in adults between the ages of 20 and 50; however, children may also be affected. The first sign of this condition is usually weight gain around the trunk and in the face. Affected individuals may get stretch marks (striae) on their thighs and abdomen and bruise easily. Individuals with Cushing disease can develop a hump on their upper back caused by abnormal deposits of fat. People with this condition can have muscle weakness, severe tiredness, and progressively thin and brittle bones that are prone to fracture (osteoporosis). They also have a weakened immune system and are at an increased risk of infections. Cushing disease can cause mood disorders such as anxiety, irritability, and depression. This condition can also affect a person's concentration and memory. People with Cushing disease have an increased chance of developing high blood pressure (hypertension) and diabetes. Women with Cushing disease may experience irregular menstruation and have excessive hair growth (hirsutism) on their face, abdomen, and legs. Men with Cushing disease may have erectile dysfunction. Children with Cushing disease typically experience slow growth.

MalaCards based summary: Pituitary Adenoma, Acth-Secreting, also known as acth-secreting pituitary adenoma, is related to canavan disease and cushing's syndrome, and has symptoms including cushingoid facies, cushingoid facies and Array. An important gene associated with Pituitary Adenoma, Acth-Secreting is USP8 (Ubiquitin Specific Peptidase 8), and among its related pathways are Glucocorticoid Pathway (HPA Axis), Pharmacodynamics and Serotonin Receptor 4/6/7 and NR3C Signaling. The drugs fluorocortisol acetate and fludrocortisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and bone, and related mouse phenotypes are neoplasm and renal/urinary system.

Disease Ontology:11 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome.

NIH Rare Diseases:48 Acth-secreting pituitary adenoma is a condition characterized by elevated levels of a hormone called cortisol secreted by a tumor in the pituitary gland. it is part of a group of diseases that cause cushing’s syndrome, characterized by signs and symptoms that may include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture (osteoporosis), mood disorders and memory problems, as well as an increased risk of infections, high blood pressure and diabetes. women may have irregular menses and a lot of hair in the body (hirsutism). it  occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol.  some cases are caused by somatic mutations in the aip and the gnas genes. rarely, an acth-secreting pituitary adenoma can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (men1) and familial isolated pituitary adenoma), but most cases are sporadic. treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels. last updated: 12/16/2015

OMIM:52 Cushing 'disease' is a condition associated with increased blood cortisol resulting from adrenocorticotropic hormone... (219090) more...

UniProtKB/Swiss-Prot:70 ACTH-secreting pituitary adenoma: A pituitary adenoma resulting in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.

Related Diseases for Pituitary Adenoma, Acth-Secreting

About this section

Diseases related to Pituitary Adenoma, Acth-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 95)
idRelated DiseaseScoreTop Affiliating Genes
1canavan disease12.3
2cushing's syndrome11.5
3pituitary-dependent cushing's disease11.1
4leukodystrophy11.0
5cerebral degeneration11.0
6myositis ossificans11.0
7mild canavan disease11.0
8severe canavan disease11.0
9mccune-albright syndrome, somatic, mosaic10.9
10malignant acth producing neoplasm of pituitary gland10.8
11lipodystrophy, familial partial, 210.7
12pituitary adenoma, growth hormone-secreting10.7
13acth-independent macronodular adrenal hyperplasia10.7
14familial partial lipodystrophy10.7
15atp7a-related copper transport disorders10.3AIP, GNAS
16cone-rod dystrophy 510.2AIP, GNAS, POMC
17burning mouth syndrome type 310.2POMC, SST
18vertebral artery occlusion10.2AIP, POMC, PRL
19renal hypoplasia, bilateral10.2POMC, SST
20water-clear cell adenoma10.2POMC, SST
21wheat allergy10.2POMC, PRL
22dacryoadenitis10.2CRH, POMC, PRL
23vaginal adenoma10.2POMC, SST
24peeling skin syndrome10.2GNAS, NR3C1, POMC
25astroblastoma10.2CRH, POMC, PRL
26pancreatic colloid cystadenoma10.2POMC, PRL
27fatty liver disease10.1CRH, POMC, PRL
28grin2a-related speech disorders and epilepsy10.1GH1, GNAS, PRL
29uterine ligament cancer10.1AIP, GNAS, SST
30acute gonococcal salpingitis10.1CRH, POMC, PRL
31glaucoma, hereditary adult type 1a10.1AIP, GH1, PRL
32keratosis10.1CRH, NR3C1, POMC
33congenital tricuspid stenosis10.1GH1, POMC, PRL
34osseous heteroplasia, progressive10.1GH1, GNAS, PRL
35olfactory nerve neoplasm10.1GH1, POMC, PRL
36lymph node cancer10.1CRH, NR3C1
37lichen disease10.1CRH, NR3C1, POMC
38caudal regression syndrome10.1GH1, POMC, PRL
39bowen-conradi syndrome10.1AIP, PRL
40breast secretory carcinoma10.1CRH, POMC, SST
41diencephalic neoplasm10.1GH1, POMC, PRL
42mucopolysaccharidosis type vi10.1GH1, POMC, PRL
43extragonadal nonseminomatous germ cell tumor10.1POMC, PRL, SST
44early-onset parkinson disease10.1CRH, POMC, SST
45macrocephaly, benign familial10.1GH1, POMC, TBX19
46pemphigus vegetans10.1GH1, SST
47leukemia, acute promyelocytic, somatic10.0GNAS, PRL, SST
48cerebral hemisphere lipoma10.0GH1, PRL, SST
49sesame syndrome10.0PCSK1, POMC, TBX19
50african histoplasmosis10.0AIP, POMC, PRL, SST

Comorbidity relations with Pituitary Adenoma, Acth-Secreting via Phenotypic Disease Network (PDN):


Rheumatoid ArthritisHypertension, Essential
OsteoporosisTemporal Arteritis
Deficiency AnemiaAdrenal Cortical Hypofunction
Respiratory FailureHeart Disease
EsophagitisPostinflammatory Pulmonary Fibrosis
Chronic Pulmonary Heart DiseaseAcute Cystitis
Oral CandidiasisHypothyroidism
Anxiety DisorderBronchitis
Status Asthmaticus

Graphical network of the top 20 diseases related to Pituitary Adenoma, Acth-Secreting:



Diseases related to pituitary adenoma, acth-secreting

Symptoms & Phenotypes for Pituitary Adenoma, Acth-Secreting

About this section

Symptoms by clinical synopsis from OMIM:

219090

Clinical features from OMIM:

219090

Human phenotypes related to Pituitary Adenoma, Acth-Secreting:

 54 64 (show all 60)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 menorrhagia64 54 Frequent (79-30%) HP:0000132
2 round face64 54 Very frequent (99-80%) HP:0000311
3 visual impairment64 54 Occasional (29-5%) HP:0000505
4 cataract64 54 Occasional (29-5%) HP:0000518
5 visual loss64 54 Occasional (29-5%) HP:0000572
6 psychosis64 54 Occasional (29-5%) HP:0000709
7 depression54 Frequent (79-30%)
8 anxiety64 54 Frequent (79-30%) HP:0000739
9 nephrolithiasis64 54 Frequent (79-30%) HP:0000787
10 infertility64 54 Frequent (79-30%) HP:0000789
11 diabetes mellitus64 54 Frequent (79-30%) HP:0000819
12 hypertension64 54 Frequent (79-30%) HP:0000822
13 osteoporosis64 54 Frequent (79-30%) HP:0000939
14 thin skin64 54 Very frequent (99-80%) HP:0000963
15 bruising susceptibility64 54 Frequent (79-30%) HP:0000978
16 acne64 54 Frequent (79-30%) HP:0001061
17 lethargy64 54 Occasional (29-5%) HP:0001254
18 failure to thrive64 54 Very frequent (99-80%) HP:0001508
19 recurrent skin infections64 54 Occasional (29-5%) HP:0001581
20 cardiomyopathy64 54 Occasional (29-5%) HP:0001638
21 truncal obesity64 54 Very frequent (99-80%) HP:0001956
22 abdominal pain64 54 Occasional (29-5%) HP:0002027
23 generalized hirsutism64 54 Frequent (79-30%) HP:0002230
24 headache64 54 Occasional (29-5%) HP:0002315
25 sleep disturbance64 54 Occasional (29-5%) HP:0002360
26 immunodeficiency64 54 Frequent (79-30%) HP:0002721
27 recurrent fractures64 54 Frequent (79-30%) HP:0002757
28 pituitary adenoma64 54 Very frequent (99-80%) HP:0002893
29 hypokalemia64 54 Frequent (79-30%) HP:0002900
30 myopathy64 54 Occasional (29-5%) HP:0003198
31 venous thrombosis64 54 Occasional (29-5%) HP:0004936
32 bipolar affective disorder64 54 Occasional (29-5%) HP:0007302
33 generalized hyperpigmentation64 54 Occasional (29-5%) HP:0007440
34 adrenal hyperplasia64 54 Very frequent (99-80%) HP:0008221
35 lipodystrophy64 54 Very frequent (99-80%) HP:0009125
36 aseptic necrosis64 54 Occasional (29-5%) HP:0010885
37 onychomycosis64 54 Occasional (29-5%) HP:0012203
38 fatigue64 54 Frequent (79-30%) HP:0012378
39 teleangiectasia of the skin54 Occasional (29-5%)
40 metrorrhagia64 54 Frequent (79-30%) HP:0100608
41 precocious menopause64 54 Occasional (29-5%) HP:0100805
42 glucose intolerance64 HP:0000833
43 oligomenorrhea64 HP:0000876
44 edema64 HP:0000969
45 purpura64 HP:0000979
46 hirsutism64 HP:0001007
47 facial erythema64 HP:0001041
48 poor wound healing64 HP:0001058
49 striae distensae64 HP:0001065
50 psychotic mentation64 HP:0001345
51 mood changes64 HP:0001575
52 alkalosis64 HP:0001948
53 kyphosis64 HP:0002808
54 vertebral compression fractures64 HP:0002953
55 increased circulating acth level64 HP:0003154
56 skeletal muscle atrophy64 HP:0003202
57 biconcave vertebral bodies64 HP:0004586
58 abdominal obesity64 HP:0012743
59 abnormal fear/anxiety-related behavior64 HP:0100852
60 telangiectasia of the skin64 HP:0100585

UMLS symptoms related to Pituitary Adenoma, Acth-Secreting:


cushingoid facies

MGI Mouse Phenotypes related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

41 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.8AIP, DRD2, GNAI2, GNAS, POMC, PRL
2MP:00053678.2CRH, DRD2, GNAS, NR3C1, POMC, PRKCD
3MP:00030127.9CRH, DRD2, GNAS, NR3C1, POMC, SST
4MP:00053757.7CRH, DRD2, GNAS, NR3C1, PCSK1, POMC
5MP:00107717.6AIP, CRH, DRD2, GNAS, NR3C1, POMC
6MP:00053847.4AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
7MP:00053857.0AIP, DRD2, GNAI2, GNAS, NR3C1, PCSK1
8MP:00053867.0CRH, DRD2, GNAI2, GNAS, NR3C1, PCSK1
9MP:00053706.9AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
10MP:00053876.4CRH, DRD2, GNAI2, GNAS, NR3C1, PCSK1
11MP:00107686.2AIP, DRD2, GNAI2, GNAS, NR3C1, PAM16
12MP:00053796.2AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
13MP:00036316.1CRH, DRD2, GNAI2, GNAS, NR3C1, POMC
14MP:00053785.9AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
15MP:00053765.6AIP, CRH, DRD2, GNAI2, GNAS, NR3C1

Drugs & Therapeutics for Pituitary Adenoma, Acth-Secreting

About this section

Drugs for Pituitary Adenoma, Acth-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 110)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SomatostatinapprovedPhase 4, Phase 3, Phase 223738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
2
ZincapprovedPhase 422967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
3
MetforminapprovedPhase 41803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
4
LiraglutideapprovedPhase 4329204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
5Hormone AntagonistsPhase 4, Phase 3, Phase 2, Early Phase 113180
6Insulin, Globin ZincPhase 44645
7insulinPhase 44646
8HormonesPhase 4, Phase 3, Phase 2, Early Phase 114415
9Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Early Phase 113168
10
LactitolPhase 4336585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
11Dipeptidyl-Peptidase IV InhibitorsPhase 4862
12Sitagliptin PhosphatePhase 4423
13
protease inhibitorsPhase 45471
Synonyms:
 
protease inhibitors
14Hypoglycemic AgentsPhase 4, Phase 25896
15HIV Protease InhibitorsPhase 45470
16IncretinsPhase 41579
17
Mifepristoneapproved, investigationalPhase 3, Phase 215584371-65-355245
Synonyms:
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
404951-53-7
83203-42-3
84371-65-3
AC1L1IOO
AC1O62SB
Ambap84371-65-3
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C-1073
C07652
C29H35NO2
CHEBI:50692
CHEMBL157
CHEMBL356066
CI-1073
CID55245
CID6445533
CPD000058481
Contragest Brand of Mifepristone
Corlux
D00585
D015735
DB00834
Dacinostat
Danco Brand of Mifepristone
EC-000.2469
EU-0100801
Exelgyn Brand of Mifepristone
FT-0082666
HMS1568L20
HMS2052L05
HMS2090L22
HSCI1_000369
HSDB 6841
I14-11726
LAQ-824
LS-192513
LS-64723
Lopac0_000801
M 8046
 
M8046_SIGMA
MLS000069785
MLS001074115
Mifegyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
Mifepristone (USAN/INN)
Mifepristone Contragest Brand
Mifepristone Danco Brand
Mifepristone Exelgyn Brand
Mifepristone [USAN:INN:BAN]
Mifepristonum
Mifepristonum [Latin]
Mifépristone
MolPort-003-849-222
NCGC00025179-05
NCGC00025179-08
NCGC00179632-01
NVP-LAQ 824
NVP-LAQ824
NVP-LAQ824, Dacinostat, LAQ824
Pictovir
Pictovir (TM)
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
Prestwick_570
R 38486
R-38486
R38486
RU 38486
RU 486
RU 486-6
RU-38486
RU-486
RU-486, MIFEPRISTONE
RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone
RU38486
RU486
S1095_Selleck
S1611_Selleck
SAM001246881
SMR000058481
SPBio_002457
Spectrum5_002045
TL8005515
UNII-320T6RNW1F
UNII-V10P524501
VGX-410
VGX-410C
VX-410
ZINC03831128
ZK 98296
ZK-98296
ZK98296
mifepristone
nchembio.313-comp12
18
Epinephrineapproved, vet_approvedPhase 3, Phase 298551-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
19
DopamineapprovedPhase 3, Phase 2383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
20
CabergolineapprovedPhase 3, Phase 24681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
21
Hydrocortisoneapproved, vet_approvedPhase 3, Phase 266750-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
22
Octreotideapproved, investigationalPhase 322383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
23
Lidocaineapproved, vet_approvedPhase 2, Phase 31317137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
24AnestheticsPhase 2, Phase 39596
25Epinephryl boratePhase 3, Phase 2985
26beta-endorphinPhase 3, Phase 2140
27Hydrocortisone 17-butyrate 21-propionatePhase 3, Phase 2667
28RacepinephrinePhase 3, Phase 2985
29Interleukin 1 Receptor Antagonist ProteinPhase 399
30Cortisol succinatePhase 3, Phase 2667
31Luteolytic AgentsPhase 3, Phase 2306
32Antirheumatic AgentsPhase 310956
33Adrenocorticotropic HormonePhase 3, Phase 2, Early Phase 1164
34Melanocyte-Stimulating HormonesPhase 3, Phase 2139
35Hydrocortisone acetatePhase 3, Phase 2667
36Antiparkinson AgentsPhase 3, Phase 21574
37Contraceptives, PostcoitalPhase 3, Phase 2175
38Dopamine AgentsPhase 3, Phase 23836
39Contraceptive AgentsPhase 3, Phase 21967
40Dopamine agonistsPhase 3, Phase 2632
41Contraceptives, OralPhase 3, Phase 21327
42Neurotransmitter AgentsPhase 3, Phase 218340
43Autonomic AgentsPhase 2, Phase 310150
44Anti-Asthmatic AgentsPhase 2, Phase 33488
45glucocorticoidsPhase 2, Phase 35103
46Respiratory System AgentsPhase 2, Phase 34997
47Vasoconstrictor AgentsPhase 2, Phase 32122
48Peripheral Nervous System AgentsPhase 2, Phase 323689
49MydriaticsPhase 2, Phase 3811
50Bronchodilator AgentsPhase 2, Phase 32965

Interventional clinical trials:

(show top 50)    (show all 55)
idNameStatusNCT IDPhase
1Adipokine Profile in Patients With Cushing's Disease on Pasireotide TreatmentCompletedNCT03080181Phase 4
2Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
3Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
4Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseCompletedNCT01374906Phase 3
5Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's DiseaseCompletedNCT00434148Phase 3
6An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.CompletedNCT01582061Phase 3
7Study of Cabergoline in Treatment of Corticotroph Pituitary TumorCompletedNCT00889525Phase 3
8Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompletedNCT01371565Phase 3
9An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3
10A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3
11Effects of IL-1 Beta on the HPA-axis in Obese PersonsCompletedNCT02227420Phase 3
12Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseRecruitingNCT02180217Phase 3
13Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseRecruitingNCT02697734Phase 3
14Ga-68-DOTATOC -PET in the Management of Pituitary TumoursRecruitingNCT02419664Phase 3
15Dynamic Hormone Diagnostics in Endocrine DiseaseNot yet recruitingNCT02934399Phase 2, Phase 3
16Mifepristone in Children With Refractory Cushing's DiseaseWithdrawnNCT01925092Phase 3
17Preoperative Bexarotene Treatment for Cushing's DiseaseUnknown statusNCT00845351Phase 1, Phase 2
18Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseUnknown statusNCT02484755Phase 2
19Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's DiseaseCompletedNCT00171951Phase 2
20A Study to Assess SOM230 in Patients With Pituitary Cushing's DiseaseCompletedNCT00088608Phase 2
21Treatment of Cushing's Disease With R-roscovitineRecruitingNCT02160730Phase 2
22Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeRecruitingNCT02468193Phase 2
23Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyRecruitingNCT00939523Phase 2
24Pasireotide LAR Therapy of Silent Corticotroph Pituitary TumorsRecruitingNCT02749227Phase 2
25Study to Evaluate CORT125134 in Patients With Cushing's SyndromeRecruitingNCT02804750Phase 2
26Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseActive, not recruitingNCT01915303Phase 2
27Safety and Efficacy of LCI699 in Cushing's Disease Patients.Active, not recruitingNCT01331239Phase 2
28Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 InhibitionNot yet recruitingNCT03111810Phase 2
29Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical TreatmentNot yet recruitingNCT02713776Phase 2
30Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)TerminatedNCT00612066Phase 2
31Rosiglitazone in Treating Patients With Pituitary TumorsTerminatedNCT00616642Phase 2
32Pasireotide Therapy in Patients With Nelson's SyndromeTerminatedNCT01617733Phase 2
33Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionTerminatedNCT00422201Phase 2
34Phase II Study of SOM230 in Patients With Recurrent or Progressive MeningiomaTerminatedNCT00813592Phase 2
35Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginTerminatedNCT00958841Phase 2
36Study of Depression, Peptides, and Steroids in Cushing's SyndromeUnknown statusNCT00004334
37Anesthesia Management of Retroperitoneal AdrenalectomiesUnknown statusNCT00894335
38The Factors Associated With the Recurrence in Patients With Cushing DiseaseCompletedNCT02233335
39Cognition, Steroids, and Imaging in Cushings DiseaseCompletedNCT00081341
40Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing SyndromeCompletedNCT00001453
41Examination of Brain Serotonin Receptors in Patients With Mood DisordersCompletedNCT00026832
42Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force ReadinessCompletedNCT01613001
43Cushing's Disease ComplicationsRecruitingNCT02568982
44Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseRecruitingNCT02310269
45Effects of Hormone Stimulation on Brain Scans for Cushing s DiseaseRecruitingNCT01459237Early Phase 1
46Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education ToolsRecruitingNCT01775332
47Mutations of Glucocorticoid Receptor in Bilateral Adrenal HyperplasiaRecruitingNCT02810496
48An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT00001595
49Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.RecruitingNCT02651844
50Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal TumorsRecruitingNCT02543697

Search NIH Clinical Center for Pituitary Adenoma, Acth-Secreting

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: acth-secreting pituitary adenoma

Genetic Tests for Pituitary Adenoma, Acth-Secreting

About this section

Anatomical Context for Pituitary Adenoma, Acth-Secreting

About this section

MalaCards organs/tissues related to Pituitary Adenoma, Acth-Secreting:

36
Pituitary, Adrenal gland, Bone, Skin, Skeletal muscle

Publications for Pituitary Adenoma, Acth-Secreting

About this section

Variations for Pituitary Adenoma, Acth-Secreting

About this section

Clinvar genetic disease variations for Pituitary Adenoma, Acth-Secreting:

5
id Gene Variation Type Significance SNP ID Assembly Location
1GNAI2NM_ 002070.3(GNAI2): c.535C> G (p.Arg179Gly)SNVPathogenicrs137853226GRCh37Chr 3, 50293694: 50293694
2GNASNM_ 000516.5(GNAS): c.680A> G (p.Gln227Arg)SNVPathogenicrs121913494GRCh37Chr 20, 57484596: 57484596
3GNASNM_ 001077488.3(GNAS): c.684G> C (p.Gln228His)SNVPathogenicrs137854533GRCh37Chr 20, 57484597: 57484597
4USP8NM_ 005154.4(USP8): c.2155_ 2157delTCC (p.Ser719del)deletionPathogenicrs672601306GRCh38Chr 15, 50490446: 50490448
5USP8NM_ 005154.4(USP8): c.2152T> C (p.Ser718Pro)SNVPathogenicrs672601307GRCh38Chr 15, 50490443: 50490443
6USP8NM_ 005154.4(USP8): c.2153C> G (p.Ser718Cys)SNVPathogenicrs672601308GRCh38Chr 15, 50490444: 50490444
7USP8NM_ 005154.4(USP8): c.2159C> G (p.Pro720Arg)SNVPathogenicrs672601311GRCh38Chr 15, 50490450: 50490450

Cosmic variations for Pituitary Adenoma, Acth-Secreting:

8 (show all 23)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM303944PIK3CApituitary,NS,adenoma,ACTHc.2984C>Ap.A995D55
2COSM27896GNASpituitary,NS,adenoma,ACTHc.680A>Gp.Q227R55
3COSM1749198USP8pituitary,NS,adenoma,ACTHc.2159C>Gp.P720R55
4COSM28544PIK3CApituitary,NS,adenoma,ACTHc.3026G>Ap.G1009E55
5COSM22589MEN1pituitary,NS,adenoma,ACTHc.1230C>Ap.F410L55
6COSM4997287USP8pituitary,NS,adenoma,ACTHc.2152T>Cp.S718P55
7COSM482HRASpituitary,NS,adenoma,ACTHc.34G>Cp.G12R55
8COSM27887GNASpituitary,NS,adenoma,ACTHc.601C>Tp.R201C55
9COSM5667CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.134C>Tp.S45F6
10COSM27895GNASadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.602G>Ap.R201H6
11COSM4167506PRKACAadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.617T>Gp.L206R6
12COSM476BRAFadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.1799T>Ap.V600E6
13COSM5663CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.133T>Cp.S45P6
14COSM4962873GNASadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.679C>Gp.Q227E6
15COSM5679CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.110C>Gp.S37C6
16COSM27899GNASadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.601C>Ap.R201S6
17COSM45444TP53adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.587G>Tp.R196L6
18COSM5681CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.95A>Gp.D32G6
19COSM225014RB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.1960G>Ap.V654M6
20COSM43555TP53adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.736A>Gp.M246V6
21COSM43939TP53skin,face,other,hyperplasiac.632C>Tp.T211I3
22COSM10654TP53skin,face,other,hyperplasiac.637C>Tp.R213*3
23COSM10995TP53skin,face,other,hyperplasiac.580C>Tp.L194F3

Expression for genes affiliated with Pituitary Adenoma, Acth-Secreting

About this section
Search GEO for disease gene expression data for Pituitary Adenoma, Acth-Secreting.

Pathways for genes affiliated with Pituitary Adenoma, Acth-Secreting

About this section

Pathways related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
19.9CRH, POMC
29.9GNAS, NR3C1
39.7CRH, GNAI2, GNAS
49.5NR3C1, POMC, PRL
59.4GNAI2, GNAS, PRKCD
69.4CRH, GNAI2, GNAS, POMC
7
Show member pathways
9.1GNAI2, GNAS, POMC, PRKCD
8
Show member pathways
9.1GNAI2, GNAS, POMC, PRKCD
9
Show member pathways
9.1DRD2, GNAI2, GNAS
10
Show member pathways
9.1CRH, GNAI2, GNAS, PRKCD
11
Show member pathways
8.8GH1, NR3C1, PRKCD, PRL
128.6DRD2, GNAI2, GNAS, PRKCD
138.4CRH, GNAI2, GNAS, POMC, PRKCD, TBX19
14
Show member pathways
8.4CRH, GH1, GNAI2, GNAS, POMC, PRKCD
15
Show member pathways
8.3GH1, GNAI2, GNAS, NR3C1, PRKCD, PRL
16
Show member pathways
6.9CRH, DRD2, GH1, GNAI2, GNAS, NR3C1

GO Terms for genes affiliated with Pituitary Adenoma, Acth-Secreting

About this section

Cellular components related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endosome lumenGO:00319049.7GH1, PRL

Biological processes related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1parturitionGO:000756710.6CRH, PRL
2JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.5GH1, PRL
3positive regulation of JAK-STAT cascadeGO:004642710.5GH1, PRL
4hormone-mediated apoptotic signaling pathwayGO:000862810.4CRH, SST
5female pregnancyGO:000756510.4CRH, GNAS, PRL
6peptide hormone processingGO:001648610.3PCSK1, POMC
7adenylate cyclase-activating adrenergic receptor signaling pathwayGO:007188010.2DRD2, GNAS
8response to nutrientGO:000758410.1GNAI2, PRL, SST
9positive regulation of receptor internalizationGO:000209210.0DRD2, GH1
10response to ethanolGO:00454719.8CRH, DRD2, PRL
11synaptic transmission, dopaminergicGO:00019639.4CRH, DRD2
12response to drugGO:00424939.0CRH, DRD2, GNAS, PRL, SST
13signal transductionGO:00071657.8AIP, CRH, DRD2, GNAI2, GNAS, NR3C1

Molecular functions related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1G-protein beta/gamma-subunit complex bindingGO:003168310.6GNAI2, GNAS
2guanyl nucleotide bindingGO:001900110.6GNAI2, GNAS
3corticotropin-releasing hormone receptor 1 bindingGO:005143010.6CRH, GNAS
4prolactin receptor bindingGO:000514810.3GH1, PRL
5ionotropic glutamate receptor bindingGO:003525510.0DRD2, GNAS
6hormone activityGO:00051799.2CRH, GH1, POMC, PRL, SST
7signal transducer activityGO:00048718.9AIP, DRD2, GNAI2, GNAS

Sources for Pituitary Adenoma, Acth-Secreting

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet